Cerenis garners $53.5M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Cerenis Therapeutics
|
$53.5M
|
TVM Capital |
Cerenis says much of the money will be used to back the development of its lead compound, Cerenis HDL, a synthetic form of HDL that mimics natural HDL. |
|
EyeGate Pharma
|
$10M
|
Innoven Partenaires and Ventech |
EyeGate is researching new drug/device therapies for macular degeneration and other eye diseases. |
|
Yaupon Therapeutics
|
$4M
|
Osage Ventures |
The financing will support the continued development of Yaupon's multiple clinical programs targeting diverse medical needs in the treatment of lymphoma, addiction and neuropathic pain. |